Search Results | Blood | American Society of Hematology

1-20 of 127

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatjana Zabelina, Wolschke Christine, Francis Ayuketang Ayuk, Ulrike Fritsche-Friedland, Axel R. Zander, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 3897.

DOI: https://doi.org/10.1182/blood-2021-153157

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Blood (2021) 138 (Supplement 1): 3926.

DOI: https://doi.org/10.1182/blood-2021-152349

Published: 2021

Journal Articles

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Maximilian Christopeit, Dietlinde Janson, Francis A. Ayuk, Christine Wolschke, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 4909.

DOI: https://doi.org/10.1182/blood-2021-152148

Published: 2021

Journal Articles

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Amin T. Turki, Christophe Peczynski, Olaf Penack, Helene Schoemans, Gerard Socie, Christian Reinhardt, Nathalie Fegueux, Didier Blaise, Nicolaus Kröger, Stephan Mielke, Jan J. Cornelissen, Patrice Chevallier, Ibrahim Yakoub-Agha, Edouard Forcade, Grzegorz W Basak, Zinaida Perić

Blood (2021) 138 (Supplement 1): 1809.

DOI: https://doi.org/10.1182/blood-2021-147724

Published: 2021

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

DOI: https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Blood (2021) 138 (Supplement 1): 1783.

DOI: https://doi.org/10.1182/blood-2021-145100

Published: 2021

Journal Articles

Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Blood (2021) 138 (Supplement 1): 1787.

DOI: https://doi.org/10.1182/blood-2021-146303

Published: 2021

Journal Articles

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Blood (2021) 138 (Supplement 1): 2818.

DOI: https://doi.org/10.1182/blood-2021-149466

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Arnold Ganser, Gerard Socie, Tobias Gedde-Dahl, Edouard Forcade, Jürgen Finke, Sr., Yves Chalandon, Claude-Eric Bulabois, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Nicolaus Kröger, Igor Wolfgang Blau, Arnon Nagler, Jordi Esteve, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 3952.

DOI: https://doi.org/10.1182/blood-2021-150306

Published: 2021

Journal Articles

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3954.

DOI: https://doi.org/10.1182/blood-2021-147684

Published: 2021

Journal Articles

Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT

Razan Mohty, Abdul Hamid Bazarbachi, Myriam Labopin, Jordi Esteve, Nicolaus Kröger, Jan J. Cornelissen, Didier Blaise, Gerard Socie, Sébastien Maury, Arnold Ganser, Jean-Henri Bourhis, Claude-Eric Bulabois, Ibrahim Yakoub-Agha, Stephanie Nguyen, Patrice Chevallier, Ali Bazarbachi, Arnon Nagler, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 2920.

DOI: https://doi.org/10.1182/blood-2021-149794

Published: 2021

Journal Articles

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Blood (2021) 138 (Supplement 1): 2876.

DOI: https://doi.org/10.1182/blood-2021-151000

Published: 2021

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

DOI: https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

Per Ljungman, MD PhD, Rafael De La Camara, MD, Malgorzata Mikulska, Gloria Tridello, Beatriz Aguado, MD, Yves Beguin, MD PhD, Rodrigo Martino Bufarull, Fabio Ciceri, MD, Lucía López Corral, MD, Claudia Crippa, MD, Dries Deeren, MD PhD, Rafael F. Duarte, MD PhD FRCP, María Laura Fox, Anna Grassi, MD, María-José Jimenez, MD, Safiye Koculu, MD, Mi Kwon, MD PhD, Juan Carlos Vallejo Llamas, Jose Luiz Lopez Lorenzo, MD, Stephan Mielke, MD, Javier López Jiménez, MD PhD, Zoraida Mesa Morales, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Rocio Parody Porras, Victoria Potter, MBBS, BSc, FRACP, FRCPA, María Suárez-Lledó, MD, Nicolaas Schaap, MD PhD, Celestine Simand, MD, Luisa Sisinni, MD, John A Snowden, MD PhD, Daniele Vallisa, MD, Ipek Yonalhindilerden, Alienor Xhaard, MD, Nina Simone Knelange, Angel Cedillo, Nicolaus Kröger, MD, Jose Luis Piñana Sanchez, Jan Styczynski, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

DOI: https://doi.org/10.1182/blood-2020-138732

Published: 2020

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 3–4.

DOI: https://doi.org/10.1182/blood-2020-137773

Published: 2020

Journal Articles

Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis

Blood (2020) 136 (Supplement 1): 38–39.

DOI: https://doi.org/10.1182/blood-2020-134173

Published: 2020

Journal Articles

Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-141792

Published: 2020

Journal Articles

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-137789

Published: 2020

Journal Articles

Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN

Blood (2020) 136 (18): 2051–2064.

DOI: https://doi.org/10.1182/blood.2019004095

Published: 2020

Includes: Supplemental data

Journal Articles

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Blood (2019) 134 (21): 1832–1846.

DOI: https://doi.org/10.1182/blood.2019000162

Published: 2019

Includes: Supplemental data

2 3 4 5

NARROW

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT

Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis

Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only